Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.
KMID : 0311120220630020179
Yonsei Medical Journal
2022 Volume.63 No. 2 p.179 ~ p.186
Da Vinci SP Single-Port Robotic Surgery in Gynecologic Tumors: Single Surgeon¡¯s Initial Experience with 100 Cases
Kwak Young-Hwa

Lee Hwa-Jung
Seon Ki-Eun
Lee Young-Joo
Lee Yong-Jae
Kim Sang-Wun
Abstract
Purpose: To report preliminary experience of single-port robotic surgery using the da Vinci SP surgical system in gynecologic tumors.

Materials and Methods: This was a retrospective study on 100 consecutive patients who underwent da Vinci SP single-port robotic surgery between November 2018 and January 2021. All procedures were performed by an experienced gynecologic surgeon using a single 2.5-cm umbilical incision.

Results: Of the 100 cases, the procedures included myomectomy (n=76), hysterectomy (n=2), endometrial cancer surgical staging (n=14), radical hysterectomy (n=3), radical trachelectomy (n=3), and ovarian cystectomy (n=2). None of the cases was converted to robotic multiport or open surgery. The median docking time was 5.0 minutes [interquartile range (IQR), 3.0?7.0], the median console time was 107.5 minutes (IQR, 78.7?155.8), and the median total operation time was 250.0 minutes (IQR, 215.0?310.0). The median estimated blood loss was 50.0 mL (IQR, 30.0?100.0), and the median change in hemoglobin level was 0.8 g/dL (IQR, 0.3?1.3). The median pain scores rated on a numerical rating scale immediately after and at 6, 12, and 24 hours after surgery were 5, 2, 2, and 2, respectively. The mean duration of postoperative hospitalization was 2.8 days.

Conclusion: Da Vinci SP single-port robotic surgery was successfully performed in various gynecologic tumors without significant complications. Therefore, this surgical system could be applied in patients who want precise gynecologic surgery while minimizing surgical incision.
KEYWORD
da Vinci SP surgical system, single-port surgery, gynecologic tumor
FullTexts / Linksout information
 
Listed journal information
SCI(E) MEDLINE ÇмúÁøÈïÀç´Ü(KCI) KoreaMed